Objective To investigate the clinical effect of dengzhanxixin injection for acute cerebral infarction (ACI) and its side effect.Methods Ninety-one patients with ACI between 6 hours and 3 days of ACI onset were randomly divided into dengzhanxixin injection treated group and danshen injection treated group(the control group). The clinical effect, the side effect and the hemorheology of two groups after treatment were observed.Results The recovery and excellence rate and the total effective rate were 60.87% and 82.61% in dengzhanxixin injection treated group, respectively, higher than danshen injection treated group, the relative data were 46.67% and 62.22%, respectively. The difference between the results of two groups was significant (P＜0.05). All parameters of hemorheology of two groups were significantly improved after treatment(P＜0.05 or P＜0.01), and there were very significant in dengzhanxixin injection group(P＜0.01).Conclusion The effect and improvement of hemorheology of dengzhanxixin injection in the treatment of ACI patients are better than danshen injection treated groups, and there no side effect. Thus,the dengzhanxixin injection is an effective and safe drug in ACI treatment.%目的 探讨灯盏细辛注射液治疗急性脑梗死患者的疗效及血液流变学的变化,并观察其不良反应.方法 选择发病时间6 h～3 d内的急性脑梗死患者91例,随机分为灯盏细辛注射液治疗组与复方丹参液对照组,观察两组疗效、治疗前后血液流变学改变和不良反应等.结果 灯盏细辛注射液治疗组基本痊愈28例(60.87%),总有效率82.61%,其疗效优于复方丹参液组(46.67%、62.22%),P＜0.05,两组治疗前后血液流变学指标变化均有明显改善(P＜0.01或P＜0.05),治疗前后差值比较差异有统计学意义,P＜0.01.结论 灯盏细辛注射液治疗急性脑梗死其疗效与血液流变学的改变优于复方丹参液,未见明显不良反应,是临床上治疗急性脑梗死有效且安全的药物.
展开▼
